A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushings disease.
A study for patients with Cushing's disease using study drug osilodrostat
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAQ8154
U.S. Govt. ID: NCT02697734
Contact: Pamela Freda: 212-305-2254 / puf1@cumc.columbia.edu
Additional Study Information: This study is for individuals who have Cushings disease and want to join voluntarily in this study to find out if a study drug called osilodrostat (LCI699) is safe and has beneficial effects in people who have Cushings disease. Cushings disease is a rare but debilitating disease. Cushings disease is caused by a benign tumor of the pituitary gland. The tumor causes the adrenal glands to secrete too much of a hormone called cortisol. Most of the harmful effects in Cushings disease are the result of too much cortisol. The purpose of this study is to confirm the effectiveness and safety of osilodrostat in treating patients with this medical condition.
This study is closed
Investigator
Pamela Freda, MD
Do You Qualify?
Have you been diagnosed with Cushing's Disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Pamela Freda
puf1@cumc.columbia.edu
212-305-2254